Issue 6/2012

  • Obama’s new biobased economy

    In this issue:

    • Cover Story: Obama’s new biobased economy - The bioeconomy begins to go truly global
    • GSK absorbs Cellzome; German biotech sector expanding
    • Abbott buys kidney treatment from Action Pharma
    • DSM enters biomedicine with takeover of Kensey Nash
    • SPECIAL: BiobasedWorld at Achema – The guide to the trade fair
    • Zeltia pockets Yondelis milestone from Johnson & Johnson
    • Selvita stuffs its war-chest with shares, grants and awards
    • Pattern of DNA methylation determines genome stability

Volume 2015

Volume 2014

Volume 2013

Volume 2012

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/6/pos/1.html?sort=desc&cHash=8305edff5982cb307c5ea48106acb36a

Kurszettel

Alle Kurse

TOP

  • MAGFORCE (D)5.25 EUR5.00%
  • SAREUM HOLDINGS (UK)0.24 GBP4.35%
  • SCANCELL HOLDINGS (UK)18.25 GBP4.29%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • IMMUPHARMA (UK)25.50 GBP-12.07%

TOP

  • EPIGENOMICS (D)4.46 EUR109.4%
  • VERONA PHARMA (UK)3.40 GBP28.3%
  • WILEX (D)2.09 EUR19.4%

FLOP

  • PROTHENA PLC (IE)34.27 USD-39.1%
  • PLETHORA (UK)2.75 GBP-33.3%
  • BIONOR PHARMA (N)0.88 NOK-30.2%

TOP

  • KARO BIO (S)26.80 SEK3728.6%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • 4SC (D)3.33 EUR291.8%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.80 SEK-85.6%
  • BIOTEST (D)14.11 EUR-84.5%
  • EVOCUTIS (UK)0.08 GBP-71.4%

No liability assumed, Date: 06.02.2016